Published on September 16, 2009 at 8:07 AM
Celsion Corporation (NASDAQ:CLSN) announced today the Company’s DIGNITY clinical trial evaluating the use of ThermoDox® in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend. The media clip, featuring Dr. Brigid M. O’Connor, Principal Investigator and Radiation Oncologist at Rhode Island Hospital, provides an overview of RCW Breast Cancer and the DIGNITY trial, which evaluates ThermoDox's potential to treat chest tumors and provide a quality of life benefit for those dealing with the disease. The informational segment ran in the Chicago, San Francisco, Los Angeles and Providence, R.I. markets on September 12th and 13th and will also appear this upcoming weekend in Los Angeles and in October in New York City during National Breast Cancer Awareness Month. A replay of the feature is posted on the Celsion website. The Company invites patients, their families, and healthcare providers to view it by selecting “Recurrent Breast Cancer Clinical Trial Video” at: www.celsion.com
Recognizing the importance of the DIGNITY Breast Cancer trial and its potential to provide a treatment of significance, Celsion has undertaken an innovative, integrated media outreach campaign. The initiatives include on-line outreach, dissemination of clinical articles and other printed material and placing TV features. The program is designed to reach a broad constituency including breast cancer patients, breast cancer support groups, oncologists and other physicians.
http://www.celsion.com
f36bb24e-a907-49df-a33b-bf3d5e8df7d2|0|.0
Posted in: Drug Trial News | Women's Health News
Tags: Breast Cancer, Cancer, Chemotherapy, Doxorubicin, Drug Delivery, Hospital, Liposome, Liver Cancer, Mastectomy, Oncology, Ultrasound